Eris Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Regulatory & Legal View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹1769.90

prior close

₹1731.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%+0.8% vs market

Pharmaceuticals peers, median of 151sector-0.3%+1.1% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+1.1

15m

+1.0

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9+0.1+0.8-0.3+1.1

Next day

+1.7-1.8+3.5-1.3+3.0

+0.0-2.9+2.9-2.5+2.5

+1.7-3.2+4.9-2.5+4.2

+0.0-1.8+1.8-1.8+1.8

-0.1-1.2+1.1-1.5+1.4

+0.0-1.1+1.1-1.6+1.6

15d

-6.2+1.9-8.2+0.6-6.8

-7.9-0.0-7.9-1.1-6.9

-8.2+1.6-9.8-3.7-4.5

-7.6-2.4-5.2-6.7-0.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences has received a show cause cum demand notice from the Directorate General of GST Intelligence (DGGI), Mumbai, alleging non-payment of Integrated GST (IGST) under the reverse charge mechanism on import of services. The notice relates to the company's 2019 acquisition of trademark rights for the diabetes brand 'Zomelis' and associated brands from Novartis AG, Switzerland. The tax demand amounts to Rs. 16.85 crore, with interest charged at 18% per annum from November 27, 2019. No penalty has been specified in the notice yet. The company is evaluating the matter with its tax consultants and plans to submit a reply within the prescribed period, stating it believes it has a strong case on merits.

Likely market impact

This is an early-stage tax dispute and not an adverse order. If the demand is upheld, it could mean an outgo of around Rs. 16.85 crore plus nearly six years of interest, which may impact short-term earnings. However, since the company intends to contest it and views its position as strong, investors should monitor the outcome but no immediate financial hit is required.